The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.

The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.

The present invention relates to cell culture media supplements or complete media compositions comprising plant-produced heterologous recombinant human albumin, as well as methods of making the cell culture media, and methods of using the supplemented cell culture media to improve viability, productivity, and growth characteristics of cultured cells.

The present invention relates to cell culture media supplements or complete media compositions comprising plant-produced heterologous recombinant human albumin, as well as methods of making the cell culture media, and methods of using the supplemented cell culture media to improve viability, productivity, and growth characteristics of cultured cells.

Methods of modifying renewable protein sources and uses thereof are provided. In some embodiments, renewable protein sources can be modified to become a flocculant and/or coagulant through the use of a hydrolysis process. Further modifications can be performed in order to enhance the flocculant/coagulant ability of the modified protein material. Such modified protein material can be used to coagulate and/or flocculate waste water colloidal suspensions, either alone or in combination with a coagulant, by mixing the modified protein material with waste water colloidal suspensions to create a mixture and allowing mixture to settle. In some embodiments, the waste water colloidal suspension can be mature fine tailings (MFT).

Methods of modifying renewable protein sources and uses thereof are provided. In some embodiments, renewable protein sources can be modified to become a flocculant and/or coagulant through the use of a hydrolysis process. Further modifications can be performed in order to enhance the flocculant/coagulant ability of the modified protein material. Such modified protein material can be used to coagulate and/or flocculate waste water colloidal suspensions, either alone or in combination with a coagulant, by mixing the modified protein material with waste water colloidal suspensions to create a mixture and allowing mixture to settle. In some embodiments, the waste water colloidal suspension can be mature fine tailings (MFT).

Provided is a biomarker for diagnosing at-risk mental state (ARMS) that may include one or more selected from the group consisting of biopyrrin, cortisol, a KFLC or a fragment thereof, and a AFLC or a fragment thereof. Further provided is an ARMS diagnosis of a subject that may be performed quickly, easily, and accurately by measuring the amount of the biomarker for diagnosing ARMS in a biological sample.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Methods for reaction electrospinning are provided to form collagen fibers. The method can include: acidifying a collagen in an acidic solvent to form an acidic collagen solution; electrospinning the acidic collagen solution within an alkaline atmosphere (e.g., including ammonia vapor) to form collagen fibers; and collecting the collagen fibers within a salt bath (e.g., including ammonium sulfate). The acidic solvent can include water and an alcohol, and can have a pH of about 2 to about 4 (e.g., including a strong acid, such as HCl). An albumin rubber is also provided, which can include albumin crosslinked with glutaraldehyde.